Skip to main content
Erschienen in: Surgery Today 4/2016

01.04.2016 | Original Article

Incidence of and risk factors for venous thromboembolism during surgical treatment for esophageal cancer: a single-institution study

verfasst von: Fumihiko Kato, Hiroya Takeuchi, Satoru Matsuda, Hirofumi Kawakubo, Tai Omori, Yuko Kitagawa

Erschienen in: Surgery Today | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

During the treatment of esophageal cancer with curative intent, patients sometimes experience deep vein thrombosis, pulmonary embolism or a central venous catheter-associated thrombus. In this study, we retrospectively reviewed our new-onset esophageal cancer patients and determined the incidence of venous thromboembolism (VTE), the location of the thrombus and the risk factors for VTE.

Methods

One hundred and fifty-three patients undergoing treatment with curative intent were reviewed as candidates. The existence of VTE was assessed from the neck to the pelvis with computed tomography at the initial visit, after neo-adjuvant chemotherapy and postoperatively.

Results

Twenty-one VTE events (13.7 %) were observed, 16 of which (76.2 %) were suggested to be associated with central venous catheterization. When both the pre-therapeutic plasma fibrinogen and C-reactive protein levels were high (≥350 mg/dL and ≥0.2 µg/mL, respectively), the risk of preoperative VTE and overall VTE were significantly higher than normal (p = 0.040, and p = 0.030, respectively). Adenocarcinoma histology and neck lymph node dissection were the independent risk factors that significantly increased the overall risk of VTE (p = 0.015, and p = 0.017, respectively).

Conclusions

This study revealed that the pre-therapeutic plasma fibrinogen level, C-reactive protein level, adenocarcinoma histology and neck lymph node dissection are the risk factors for venous thromboembolism in patients with esophageal cancer undergoing treatment with curative intent.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed
2.
Zurück zum Zitat Herskovic A, Martz K, al Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.CrossRefPubMed Herskovic A, Martz K, al Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.CrossRefPubMed
3.
Zurück zum Zitat Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999;281:1623–7 (Radiation Therapy Oncology Group).CrossRefPubMed Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999;281:1623–7 (Radiation Therapy Oncology Group).CrossRefPubMed
4.
Zurück zum Zitat Shitara K, Muro K. Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives. Gastrointest Cancer Res. 2009;3:66–72.PubMedCentralPubMed Shitara K, Muro K. Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives. Gastrointest Cancer Res. 2009;3:66–72.PubMedCentralPubMed
5.
6.
Zurück zum Zitat Fujita H, Kakegawa T, Yamana H, Shima I, Toh Y, Tomita Y, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg. 1995;222:654–62.PubMedCentralCrossRefPubMed Fujita H, Kakegawa T, Yamana H, Shima I, Toh Y, Tomita Y, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg. 1995;222:654–62.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246:992–1001.CrossRefPubMed Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246:992–1001.CrossRefPubMed
8.
Zurück zum Zitat Kaburagi T, Takeuchi H, Kawakubo H, Omori T, Ozawa S, Kitagawa Y. Clinical utility of a novel hybrid position combining the left lateral decubitus and prone positions during thoracoscopic esophagectomy. World J Surg. 2014;38:410–8.CrossRefPubMed Kaburagi T, Takeuchi H, Kawakubo H, Omori T, Ozawa S, Kitagawa Y. Clinical utility of a novel hybrid position combining the left lateral decubitus and prone positions during thoracoscopic esophagectomy. World J Surg. 2014;38:410–8.CrossRefPubMed
9.
Zurück zum Zitat Virchow R. Thrombose und Embolie. In: Gesammelte Abhandlungen zur Wissenschaftlichen Medicin (in German). Verlag von Meidinger Sohn and Comp, Frankfurt; 1856. p. 219–732. Virchow R. Thrombose und Embolie. In: Gesammelte Abhandlungen zur Wissenschaftlichen Medicin (in German). Verlag von Meidinger Sohn and Comp, Frankfurt; 1856. p. 219–732.
10.
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Oxford: Blackwell; 2009. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Oxford: Blackwell; 2009.
11.
Zurück zum Zitat Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999;78:285–91.CrossRefPubMed Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999;78:285–91.CrossRefPubMed
12.
Zurück zum Zitat Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, et al. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2008;21:575–81.CrossRefPubMed Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, et al. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2008;21:575–81.CrossRefPubMed
13.
Zurück zum Zitat Rollins KE, Peters CJ, Safranek PM, Ford H, Baglin TP, Hardwick RH. Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery. Eur J Surg Oncol. 2011;37:1072–7.CrossRefPubMed Rollins KE, Peters CJ, Safranek PM, Ford H, Baglin TP, Hardwick RH. Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery. Eur J Surg Oncol. 2011;37:1072–7.CrossRefPubMed
14.
Zurück zum Zitat Tsutsumi K, Udagawa H, Kajiyama Y, Kinoshita Y, Ueno M, Nakamura T, et al. Pulmonary thromboembolism after surgery for esophageal cancer: its features and prophylaxis. Surg Today. 2000;30:416–20.CrossRefPubMed Tsutsumi K, Udagawa H, Kajiyama Y, Kinoshita Y, Ueno M, Nakamura T, et al. Pulmonary thromboembolism after surgery for esophageal cancer: its features and prophylaxis. Surg Today. 2000;30:416–20.CrossRefPubMed
15.
Zurück zum Zitat Trousseau A, Bazire PV, Cormack JR. Lectures on clinical medicine. London: R. Hardwicke; 1867. Trousseau A, Bazire PV, Cormack JR. Lectures on clinical medicine. London: R. Hardwicke; 1867.
16.
Zurück zum Zitat Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–4.CrossRefPubMed Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–4.CrossRefPubMed
17.
Zurück zum Zitat Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–50.CrossRefPubMed Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–50.CrossRefPubMed
18.
Zurück zum Zitat Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol. 2007;22:2222–7.CrossRefPubMed Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol. 2007;22:2222–7.CrossRefPubMed
19.
Zurück zum Zitat Matsuda S, Takeuchi H, Fukuda K, Nakamura R, Takahashi T, Wada N, et al. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment. Dis Esophagus. 2014;27:654–61.CrossRefPubMed Matsuda S, Takeuchi H, Fukuda K, Nakamura R, Takahashi T, Wada N, et al. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment. Dis Esophagus. 2014;27:654–61.CrossRefPubMed
20.
Zurück zum Zitat Koukourakis MI, Kambouromiti G, Pitsiava D, Tsousou P, Tsiarkatsi M, Kartalis G. Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication. Inflammation. 2009;32:169–75.CrossRefPubMed Koukourakis MI, Kambouromiti G, Pitsiava D, Tsousou P, Tsiarkatsi M, Kartalis G. Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication. Inflammation. 2009;32:169–75.CrossRefPubMed
21.
Zurück zum Zitat Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost. 2009;102:615–9.PubMedCentralPubMed Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost. 2009;102:615–9.PubMedCentralPubMed
22.
Zurück zum Zitat Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol. 2009;27:3786–93.CrossRefPubMed Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol. 2009;27:3786–93.CrossRefPubMed
23.
Zurück zum Zitat Mino JS, Gutnick JR, Monteiro R, Anzlovar N, Siperstein AE. Line-associated thrombosis as the major cause of hospital-acquired deep vein thrombosis: an analysis from National Surgical Quality Improvement Program data and a call to reassess prophylaxis strategies. Am J Surg. 2014;208:45–9.CrossRefPubMed Mino JS, Gutnick JR, Monteiro R, Anzlovar N, Siperstein AE. Line-associated thrombosis as the major cause of hospital-acquired deep vein thrombosis: an analysis from National Surgical Quality Improvement Program data and a call to reassess prophylaxis strategies. Am J Surg. 2014;208:45–9.CrossRefPubMed
24.
Zurück zum Zitat Lieberman JS, Borrero J, Urdaneta E, Wright IS. Thrombophlebitis and cancer. JAMA. 1961;177:542–5.CrossRefPubMed Lieberman JS, Borrero J, Urdaneta E, Wright IS. Thrombophlebitis and cancer. JAMA. 1961;177:542–5.CrossRefPubMed
25.
Zurück zum Zitat Sack GH Jr, Levin J, Bell WR. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977;56:1–37.CrossRef Sack GH Jr, Levin J, Bell WR. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977;56:1–37.CrossRef
26.
Zurück zum Zitat Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2004;2:1760–5.CrossRefPubMed Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2004;2:1760–5.CrossRefPubMed
27.
Zurück zum Zitat Hata T, Yasui M, Murata K. Safety of fondaparinux to prevent venous thromboembolism in Japanese patients undergoing colorectal cancer surgery: a multicenter study. Surg Today. 2014;44:2116–23.PubMedCentralCrossRefPubMed Hata T, Yasui M, Murata K. Safety of fondaparinux to prevent venous thromboembolism in Japanese patients undergoing colorectal cancer surgery: a multicenter study. Surg Today. 2014;44:2116–23.PubMedCentralCrossRefPubMed
Metadaten
Titel
Incidence of and risk factors for venous thromboembolism during surgical treatment for esophageal cancer: a single-institution study
verfasst von
Fumihiko Kato
Hiroya Takeuchi
Satoru Matsuda
Hirofumi Kawakubo
Tai Omori
Yuko Kitagawa
Publikationsdatum
01.04.2016
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 4/2016
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-015-1196-1

Weitere Artikel der Ausgabe 4/2016

Surgery Today 4/2016 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 49 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Sechs Maßnahmen gegen Regelschmerzen – von Krafttraining bis Yoga

05.06.2024 Dysmenorrhö Nachrichten

Um herauszufinden, wie gut sich körperliche Übungen dafür eignen, primäre Dysmenorrhö zu lindern, hat eine Studiengruppe sechs verschiedene Verfahren untersucht. Alle wirkten, doch eine Methode war Favorit.

Intoxikation ohne Alkoholaufnahme: An das Eigenbrauer-Syndrom denken!

05.06.2024 Internistische Diagnostik Nachrichten

Betrunken trotz Alkoholabstinenz? Der Fall einer 50-jährigen Patientin zeigt, dass dies möglich ist. Denn die Frau litt unter dem Eigenbrauer-Syndrom, bei dem durch Darmpilze eine alkoholische Gärung in Gang gesetzt wird.

Diplom, Diplom an der Wand: Wie man in der Telemedizin seriös wirkt

04.06.2024 Telemedizin Nachrichten

Seit den Zeiten der Coronapandemie sind telemedizinische Arztkonsultationen zur Normalität geworden. Wie Frau oder Herr Doktor dabei im günstigsten Licht erscheinen, hat eine Patientenbefragung eruiert.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.